Display options
Cite
Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol. 2014;7(4):167-75doi: 10.1177/1756283X14528269.
Acosta, A., & Camilleri, M. (2014). Elobixibat and its potential role in chronic idiopathic constipation. Therapeutic advances in gastroenterology, 7(4), 167-75. https://doi.org/10.1177/1756283X14528269
Acosta, Andres, and Camilleri, Michael. "Elobixibat and its potential role in chronic idiopathic constipation." Therapeutic advances in gastroenterology vol. 7,4 (2014): 167-75. doi: https://doi.org/10.1177/1756283X14528269
Acosta A, Camilleri M. Elobixibat and its potential role in chronic idiopathic constipation. Therap Adv Gastroenterol. 2014 Jul;7(4):167-75. doi: 10.1177/1756283X14528269. PMID: 25057297; PMCID: PMC4107709.
Copy Download .nbib Format: NLM
Share it on

Therap Adv Gastroenterol. 2014 Jul;7(4):167-75. doi: 10.1177/1756283X14528269.

Elobixibat and its potential role in chronic idiopathic constipation.

Therapeutic advances in gastroenterology

Andres Acosta, Michael Camilleri

Affiliations

  1. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, Rochester, MN, USA.
  2. Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Mayo Clinic, 200 First St SW, Charlton Building, Room 8-110, Rochester, MN 55905, USA.

PMID: 25057297 PMCID: PMC4107709 DOI: 10.1177/1756283X14528269

Abstract

Chronic idiopathic constipation is highly prevalent among adults. Bile acids (BAs) and the enterohepatic BA circulation modulate colonic secretion and motility that affect transit. BAs in the colon have a dual action as osmotic and stimulant agents. Newer agents, such as elobixibat (A3309), an inhibitor of the ileal BA transporter, have the potential to improve significantly the management of chronic constipation, with minimal adverse effects. Elobixibat modulates the enterohepatic BA circulation, enhancing the delivery of BAs to the colon where they induce secretory and motor effects. Secondary effects of the inhibition of BA absorption are reduced activation of the farnesoid X receptor, decreased secretion of fibroblast growth factor-19 into the portal circulation, and increased BA synthesis. This review focuses on the role of BAs, the enterohepatic BA circulation, and an ileal BA transporter inhibitor (elobixibat) in chronic constipation.

Keywords: A3309; IBS-C; bile acid transporter; functional constipation

References

  1. Am J Physiol Gastrointest Liver Physiol. 2002 Mar;282(3):G443-9 - PubMed
  2. Aliment Pharmacol Ther. 2011 Jul;34(1):41-50 - PubMed
  3. J Clin Invest. 1995 Mar;95(3):1235-43 - PubMed
  4. Aliment Pharmacol Ther. 2009 Feb 1;29(3):329-41 - PubMed
  5. Am J Gastroenterol. 2011 Dec;106(12):2154-64 - PubMed
  6. Clin Gastroenterol Hepatol. 2009 Nov;7(11):1189-94 - PubMed
  7. Arch Intern Med. 1998 Jun 8;158(11):1253-61 - PubMed
  8. Gastroenterology. 2013 Jan;144(1):211-7 - PubMed
  9. J Clin Invest. 1971 Aug;50(8):1569-77 - PubMed
  10. Dis Colon Rectum. 2002 Sep;45(9):1233-41 - PubMed
  11. Neurogastroenterol Motil. 2011 Nov;23(11):995-9, e458 - PubMed
  12. Expert Rev Gastroenterol Hepatol. 2014 Jan;8(1):49-61 - PubMed
  13. Neurogastroenterol Motil. 2010 Jul;22(7):814-25, e227-8 - PubMed
  14. Clin Gastroenterol Hepatol. 2012 Sep;10(9):1009-15.e3 - PubMed
  15. Am J Gastroenterol. 2011 Oct;106(10):1803-12 - PubMed
  16. Gastroenterology. 2001 Feb;120(2):354-60 - PubMed
  17. Gastroenterology. 2010 Nov;139(5):1549-58, 1558.e1 - PubMed
  18. N Engl J Med. 2012 Oct 25;367(17):1626-35 - PubMed
  19. Gut. 2012 Aug;61(8):1132-9 - PubMed
  20. J Clin Invest. 2013 Oct;123(10):4111-20 - PubMed
  21. Nutr Cancer. 1982;4(1):67-73 - PubMed
  22. Dig Dis Sci. 2011 Jun;56(6):1619-25 - PubMed
  23. Aliment Pharmacol Ther. 2007 Mar 1;25(5):599-608 - PubMed
  24. N Engl J Med. 2008 May 29;358(22):2344-54 - PubMed
  25. Gastroenterology. 2010 Jan;138(1):89-97 - PubMed
  26. Curr Gastroenterol Rep. 2011 Oct;13(5):418-25 - PubMed
  27. Clin Gastroenterol Hepatol. 2010 Feb;8(2):159-65 - PubMed
  28. Am J Physiol Gastrointest Liver Physiol. 2014 Jan 1;306(1):G13-26 - PubMed
  29. N Engl J Med. 2003 Oct 2;349(14):1360-8 - PubMed
  30. Front Biosci (Landmark Ed). 2009 Jan 01;14:2584-98 - PubMed
  31. N Engl J Med. 2011 Aug 11;365(6):527-36 - PubMed
  32. Gastroenterology. 2013 Jan;144(1):145-54 - PubMed
  33. Eur J Cancer Prev. 2000 Oct;9(5):317-23 - PubMed
  34. Drugs. 1981 Feb;21(2):90-119 - PubMed
  35. Clin Gastroenterol Hepatol. 2013 Oct;11(10):1270-1275.e1 - PubMed
  36. Gastroenterology. 2006 Apr;130(5):1480-91 - PubMed
  37. Gastroenterology. 2011 Jun;140(7):1934-42 - PubMed
  38. Gastroenterology. 2013 Jan;144(1):218-38 - PubMed
  39. Gastroenterology. 2007 Sep;133(3):761-8 - PubMed
  40. Ann Surg. 2010 Jun;251(6):1034-40 - PubMed
  41. Hepatology. 2012 Dec;56(6):2404-11 - PubMed
  42. J Lipid Res. 2007 Dec;48(12):2693-700 - PubMed
  43. Yonsei Med J. 2008 Oct 31;49(5):792-803 - PubMed

Publication Types

Grant support